Stanazol 10mg
€ 39,00
10 mg · 100 tablets · Oral research compound — Stanozolol 10 mg is a fast-acting, DHT-derived anabolic agent ideal for lean-mass studies, strength research, and bronchodilation protocols. With ~100% bioavailability and a 4–6 h half-life, it enables precise short-cycle sampling for PK/PD models.
Brand: Magnus Pharmaceuticals
Content: 100 tablets | 10 mg per tablet
Price: €39
Manufactured in: Europe
Stanozolol 10 mg is a fast-acting, 17-α-alkylated DHT-derived oral anabolic agent originally known as Winstrol. It is widely used in research focused on lean muscle development, nitrogen retention, and muscle hardening, as well as airway-fat loss and bronchodilation protocols.
Its high oral bioavailability (~100%) and short 4–6 hour half-life support multiple daily sampling in pharmacokinetic and pharmacodynamic studies. Peak plasma concentrations are reached within 1–2 hours. Due to long-detectable urinary metabolites, any exposure is virtually guaranteed to result in a positive anti-doping test.
✅ Key Research HighlightsAnabolic effects: Rapid lean-mass gain, nitrogen retention, and enhanced FEV₁ within 30 minutes
AR-binding ratio: ~2–4× higher myotrophic potency vs testosterone, with reduced androgenicity
Endurance support: Increases hemoglobin and hematocrit in animal and human studies
Cholestatic risk: Liver stress and rare failure cases reported at 30–50 mg/day chronic use
Lipid warning: Decreases HDL and increases LDL; caution advised in long-term trials
Cardiovascular strain: β₂-agonist action may cause tremor, tachycardia, and electrolyte shifts
WADA compliance: Listed on S1 banned substances with 8+ day urine detection via LC-MS/MS
Lean mass and cutting-phase muscle modeling
Pulmonary recovery and airway-opening protocols
Nitrogen balance and protein metabolism studies
Erythropoiesis and red blood cell enhancement trials
📊 Technical Specifications| Field | Data |
|---|---|
| Chemical Name | Stanozolol |
| Chemical Formula | C21H32N2O |
| Synonyms | Winstrol, Androstanazole, 17α-methyl-2′H-5α-androstan[3,2-c]pyrazol-17-ol |
| Molecular Weight | 328.49 g/mol |
| CAS Number | 10418-03-8 |
| Dose / Pack | 10 mg × 100 tablets (1,000 mg total) |
| Half-life (oral) | ≈ 4–6 hours; peak Cmax at 1–2 h |
| Key Benefits | Rapid lean-mass gain, ↑ RBC count, zero aromatisation |
| Main Risks | Hepatotoxicity, HDL↓/LDL↑, tremor, tachycardia, cholestasis |
| Detection Window | ≥ 8 days (urinary 17-epi metabolites) |
| Storage / Shelf-life | Store ≤ 25 °C · 36-month shelf-life (manufacturer specification) |
Enhances lean-muscle gain and nitrogen retention
Improves endurance via red-blood cell stimulation
No aromatization risk — useful in estrogen-sensitive protocols
Documented hepatotoxicity risk with supra-therapeutic dosing
Alters lipid profiles; monitor HDL/LDL during long-term trials
⚠️ Documented Research Side EffectsLiver stress and cholestasis at high doses
HDL suppression and LDL elevation
Cardiovascular symptoms: tremor, tachycardia, hypokalemia
Long detection window in urine (WADA S1 listed)
🧯 Handling & ComplianceFor Research Use Only — Not for human or veterinary use
Store at 15–25°C, away from light
Follow SDS guidelines for safe handling and disposal
Purchase confirms qualified researcher status
Related products
Reviews
Clear filtersThere are no reviews yet.